Core Viewpoint - 康希诺's stock closed at 79.70 yuan, experiencing a decline of 4.93%, indicating it is currently in a state of underperformance since its IPO [1] Group 1: IPO Details - 康希诺 was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 13, 2020, with an issuance of 24.8 million shares at a price of 209.71 yuan per share [1] - The total funds raised by 康希诺 amounted to 5.201 billion yuan, with a net amount of 4.979 billion yuan after deducting issuance costs, which was 3.979 billion yuan more than the original plan [1] - The company initially aimed to raise 1 billion yuan for various projects, including the construction of a second production base and vaccine development [1] Group 2: Issuance Costs - The issuance costs for 康希诺 totaled 221 million yuan, with underwriting and sponsorship fees accounting for 205 million yuan [2] - 中信证券投资有限公司 received 496,000 shares, representing 2.00% of the total shares issued, with an investment amount of 104 million yuan [2]
康希诺跌4.93% 2020年上市募52亿中信证券保荐